nach oben

Erschienen in:

01.03.2014 | Original Article

Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients

verfasst von: Thomas S. Y. Chan, Harinder Gill, Yu-Yan Hwang, Joycelyn Sim, Alan C. T. Tse, Florence Loong, Pek-Lan Khong, Eric Tse, Anskar Y. H. Leung, Chor-Sang Chim, Albert K. W. Lie, Yok-Lam Kwong

Erschienen in: Annals of Hematology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

The frequency of breakthrough invasive fungal diseases (IFDs) during echinocandin therapy is unclear. We retrospectively analyzed 534 hematologic patients treated with echinocandin (caspofungin, N = 55; micafungin, N = 306; anidulafungin, N = 173). Four proven IFDs were found, caused by Candida parapsilosis (N = 2), C. parapsilosis and Candida glabrata (N = 1), and Fusarium species (N = 1). Four cases of possible IFDs were observed, all showing pulmonary infection. One case showed features suggestive of hepatosplenic candidiasis. Six of these eight cases had previously received the purine analog clofarabine. Breakthrough IFD during echinocandin treatment occurred infrequently (1.5 %), caused predominantly by Candida species. Clofarabine usage was an important risk factor.

Chen SC, Slavin MA, Sorrell TC (2011) Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11–41CrossRefPubMed

Sun HY, Singh N (2010) Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents 35:211–8CrossRefPubMed

De Pauw B, Walsh TJ, Donnelly JP et al (2008) European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–21CrossRefPubMedCentralPubMed

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ et al (2011) Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52:e56–93CrossRefPubMed

Tse E, Leung AY, Sim J et al (2011) Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Ann Hematol 90:1277–81CrossRefPubMedCentralPubMed

Ortega M, Marco F, Soriano A et al (2011) Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect 77:157–61CrossRefPubMed

Pfaller M, Boyken L, Hollis R et al (2011) Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol 49:624–9CrossRefPubMedCentralPubMed

Pfaller MA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125(1 Suppl):S3–13CrossRefPubMed

Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS (2008) A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52:2305–12CrossRefPubMedCentralPubMed

10.

Pang KA, Godet C, Fekkar A et al (2012) Breakthrough invasive mould infections in patients treated with caspofungin. J Infect 64:424–9CrossRefPubMed

11.

Chan TS, Hwang YY, Gill H et al (2013) Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital. Intern Med J 43(5):541–6CrossRefPubMed

Titel: Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients
verfasst von: Thomas S. Y. Chan
Harinder Gill
Yu-Yan Hwang
Joycelyn Sim
Alan C. T. Tse
Florence Loong
Pek-Lan Khong
Eric Tse
Anskar Y. H. Leung
Chor-Sang Chim
Albert K. W. Lie
Yok-Lam Kwong
Publikationsdatum: 01.03.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 3/2014
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-013-1882-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients

Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy

Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay

Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report

Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma

Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin